Latest Post
Showing posts with label SMOKING RESEARCH. Show all posts
Showing posts with label SMOKING RESEARCH. Show all posts

Use Social Media in Study of E-Cigarettes

Written By Unknown on Sunday, February 1, 2015 | 7:50 PM

Five-year grant from the National Institutes of Health will support project that is as much about data-gathering methods as it is about public health. Credit: UA

When Facebook announced in September that it would use all that personal data it collects to roll out a new ad platform to rival Google, privacy advocates groaned and marketers grinned.

But what if all that intelligence could be used to crack open one of today’s most pressing — yet least understood — public health issues?

That’s precisely the vision of the University of Arizona’s Daniel Zeng, MIS professor at the Eller College of Management, and Scott Leischow, adjunct faculty in the UA College of Medicine and professor of health services research at Arizona’s Mayo Clinic.

Fusing cutting-edge informatics and public health, their plan to scrape social media to create the world’s best data on e-cigarette usage and marketing recently won a five-year, $2.7 million grant from the National Institutes of Health.

The project will tackle four distinct goals. It will:

Create a massive, real-time and continuously growing data set of what consumers and marketers say about e-cigarettes on sites such as Facebook and Twitter, as well as social media forums focused on e-cigarettes and "vaping."

Mine that content for insights into why people use e-cigarettes, how they believe they affect their health and whether they help them quit smoking.

Document the marketing landscape — all the ways brands and vendors use these channels to promote their products and how consumers respond.

Integrate all of that information in the world’s first one-stop resource for wide-ranging data on e-cigarettes as revealed through social media as a tool for other researchers, health care professionals and more.

While e-cigarettes are relatively new in the U.S. — they were introduced in 2007 — sales are doubling annually and were expected to reach $1 billion last year. Even so, any time public dollars fund research, two questions naturally arise: Why study this? And why study it this way?

"There’s so much we don’t know about e-cigarettes," Leischow says. "The scientific community has found mixed data on whether they’re helpful for smoking cessation. We have questions about how different flavorings impact use, particularly among minors. And many health professionals worry that e-cigarettes may ultimately lead to more young people taking up smoking. All of these blind spots around a product that is still totally unregulated make this a top-priority area for the FDA."

As for why it makes sense to study e-cigarettes in this way, Zeng’s MIS expertise holds the key.  By mining social media in real time, as Zeng and Leischow have proposed, there are a number of strategic advantages:

Data comes from people interacting naturally in their day-to-day lives, thus removing “presentation bias” problems intrinsic in surveys.

The data collection is automated, which means sample size is not constrained by how much money or how many eyeball hours researchers can muster.

The lack of constraint also makes anecdotal information scientifically relevant: One personal story is just that, but 10,000 or 100,000 personal stories over time equal robust statistical data.

Because content is processed by algorithms, not people, data is available in near real time, not months or even years after countless hours of labor-intensive review.

The world of e-cigarettes, like that of any niche product or interest, has its own specialized vocabulary of acronyms and slang, so the research team will first need to construct a base lexical dataset for “training” the computers that will collect and process content.

It’s also one thing to scrape words but a much more complex challenge to automate the process of extracting meaning, so that a computer can spot when someone cites a reason for using e-cigarettes or mentions how the products affect his or her health (both of which first require a computer to detect who is or isn’t a user) or correctly catalog the marketing strategy used in an advertisement.

"We basically will be creating a suite of novel technologies for this study using both established building blocks of informatics and methods that have yet to be developed," Zeng says, "including analysis and visualization tools that were developed here at the U of A. 
Beyond that, we’re relying on proven tools for pattern mining, group behavior prediction, social network analysis and a lot more, but in ways that have never been combined for this level of research and in this topic area."

For Leischow, the knowledge those tools will produce is invaluable.

"There are all kinds of messages out there, from how effective e-cigarettes can be to help smokers quit tobacco to how they’re totally harmless or taste like candy," he says. "It may be that e-cigarettes prove beneficial to public health, or they may be shown to do more harm than good. In either case, it often takes many years for experts to fully recognize how products are being used and how they impact well-being, and even longer for regulation to catch up.

"This time, it’s going to be different. This time, we’re getting out ahead."

Source: UA

New Zealand leads research on natural quit smoking remedy

Written By Unknown on Thursday, January 29, 2015 | 12:40 AM

New Zealand researchers have found that a low cost, plant-based product marketed for smoking cessation in parts of Europe for the last 40 years, is better than nicotine replacement therapy at helping smokers quit. 

Trial results show that the compound cytisine is more effective than nicotine replacement therapy (NRT) at helping smokers quit.

The trial is the first of its kind in the world and was carried out by the National Institute for Health Innovation at the University of Auckland.  The study results were published recently in the top-rated international medical journal, the New England Medical Journal.

Cytisine is a natural, plant-based compound that has been used in smoking cessation for more than 40 years in Eastern Europe and is commercially produced in Bulgaria and Poland.  The trial followed 1310 adult daily smokers who called the national Quitline in New Zealand.

 Smokers were randomly assigned to receive either cytisine for 25 days or eight weeks of NRT. Participants in both groups also received telephone-based Quitline behavioural support.

Results indicated that after using cytisine for 25 days, a smoker was more likely to have quit smoking at six months, compared to using NRT. Compared to NRT, cytisine users experienced a slight increase in side effects; the most common of which were nausea, vomiting and sleep disturbances.

 “Placebo-controlled trials showed that cytisine almost doubles the chances of still being smoke-free at six months,” says study senior author, Dr Natalie Walker, who is the Heart Foundation Douglas Senior Research Fellow (Prevention) at the University of Auckland’s National Institute for Health Innovation. “We wanted to see how effective cytisine was compared to NRT at helping smokers quit.”

 In New Zealand and many other Western countries NRT is the most common medication used to support people to quit smoking.

 Cytisine is an alkaloid which naturally occurs in the Golden Rain (Laburnum anagyroides) and other members of the Fabaceae plant family.

“To the brain cytisine looks a little like nicotine and so it works to alleviate any urges to smoke and reduces the severity of nicotine withdrawal symptoms.  Plus, if you do smoke whilst using cytisine it will be less satisfying - making quitting easier”, says Dr Walker.

Cytisine is a similar type of drug to varenicline (the most effective smoking cessation treatment available, marketed by Pfizer), but is substantially cheaper (cytisine: US$20-$30 for 25-days, NRT: US$112-$685 for 8-10 weeks, varenicline: US$474-501 for 12 weeks).

“There is a big opportunity for low and middle income countries to access a low priced quit remedy,” says Dr Walker. “It’s great for countries that cannot afford more expensive smoking cessation medicines.”

Cytisine is licensed for use as an ‘over the counter’ medication, on prescription or via the internet in a number of Central and Eastern European countries, but it is not yet available in New Zealand.  

“Internationally, very few researchers are undertaking research on the use of cytisine for smoking cessation,” says Associate Professor Chris Bullen, Director of the National Institute for Health Innovation.

“Researchers at the University of Auckland are leading the way.  For example, other researchers in the Department of Pharmacology and at the School of Pharmacy are looking at how cytisine is absorbed and metabolised by the body,” he says.

The trial is funded by the Health Research Council of New Zealand and is one of a number of studies the Institute have undertaken to find innovative options for smokers to stop smoking to achieve smoke-free New Zealand by 2025.  The last trial they completed was one involving e-cigarettes

The study, ‘Randomized comparison of cytisine versus nicotine for smoking cessation’, by Dr Natalie Walker (National Institute for Health Innovation, University of Auckland), Dr Colin Howe (NIHI), Dr Marewa Glover (Centre for Tobacco Control Research, UoA), Dr Hayden McRobbie (Queen Mary University London), Associate Professor Jo Barnes (School of Pharmacy, UoA), Dr Vili Nosa (UoA), Ms Varsha Parag (NIHI), Mr Bruce Bassett (Quit Group), Associate Professor Chris Bullen (Director, NIHI).

Source: Auckland University
 
Support : Creating Website | Johny Template | Mas Template
Copyright © 2011. The planet wall - All Rights Reserved
Template Created by Easy Blogging Published by Mas Template
Proudly powered by Blogger